Deferiprone for transfusional iron overload and its roles in developing countries

Introduction: Variations in chelation efficacy and adverse events in particular neutropenia and agranulocytosis relegate deferiprone (DFP) to a second-line therapy in iron overload patients in whom iron chelation with deferoxamine (DFO) is inadequate. With a major economical constraint, many patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Vip Viprakasit, Sarayuth Rodmai, Somdet Srichairatanakool
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84896702474&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53835
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-53835
record_format dspace
spelling th-cmuir.6653943832-538352018-09-04T10:00:38Z Deferiprone for transfusional iron overload and its roles in developing countries Vip Viprakasit Sarayuth Rodmai Somdet Srichairatanakool Medicine Pharmacology, Toxicology and Pharmaceutics Introduction: Variations in chelation efficacy and adverse events in particular neutropenia and agranulocytosis relegate deferiprone (DFP) to a second-line therapy in iron overload patients in whom iron chelation with deferoxamine (DFO) is inadequate. With a major economical constraint, many patients who have no access to DFO or deferasirox in developing countries have started to use DFP as their first option. It is of interest to review the clinical pharmacology and latest clinical experiences with DFP to determine its role in the developing world. Areas covered: This review describes the preclinical and clinical data of DFP in patients with transfusional iron overload by searching with the keywords 'deferiprone' and 'iron overload' using the PubMed database. A projection of iron chelation cost per year was estimated based on the market price of all available iron chelators in 2013 and expected number of thalassemia patients who require chelation therapy in Thailand as an example. Expert opinion: Through a comprehensive program of medical education and continuous monitoring with appropriate clinical guidelines, DFP can be used with acceptable efficacy and safety. In patients who do not respond well to DFP monotherapy and/or require intensive chelation due to cardiac iron overload, a combination of DFP and DFO is highly recommended. © Informa UK, Ltd. 2018-09-04T09:58:59Z 2018-09-04T09:58:59Z 2014-01-01 Journal 21678707 2-s2.0-84896702474 10.1517/21678707.2014.885388 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84896702474&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/53835
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
Pharmacology, Toxicology and Pharmaceutics
spellingShingle Medicine
Pharmacology, Toxicology and Pharmaceutics
Vip Viprakasit
Sarayuth Rodmai
Somdet Srichairatanakool
Deferiprone for transfusional iron overload and its roles in developing countries
description Introduction: Variations in chelation efficacy and adverse events in particular neutropenia and agranulocytosis relegate deferiprone (DFP) to a second-line therapy in iron overload patients in whom iron chelation with deferoxamine (DFO) is inadequate. With a major economical constraint, many patients who have no access to DFO or deferasirox in developing countries have started to use DFP as their first option. It is of interest to review the clinical pharmacology and latest clinical experiences with DFP to determine its role in the developing world. Areas covered: This review describes the preclinical and clinical data of DFP in patients with transfusional iron overload by searching with the keywords 'deferiprone' and 'iron overload' using the PubMed database. A projection of iron chelation cost per year was estimated based on the market price of all available iron chelators in 2013 and expected number of thalassemia patients who require chelation therapy in Thailand as an example. Expert opinion: Through a comprehensive program of medical education and continuous monitoring with appropriate clinical guidelines, DFP can be used with acceptable efficacy and safety. In patients who do not respond well to DFP monotherapy and/or require intensive chelation due to cardiac iron overload, a combination of DFP and DFO is highly recommended. © Informa UK, Ltd.
format Journal
author Vip Viprakasit
Sarayuth Rodmai
Somdet Srichairatanakool
author_facet Vip Viprakasit
Sarayuth Rodmai
Somdet Srichairatanakool
author_sort Vip Viprakasit
title Deferiprone for transfusional iron overload and its roles in developing countries
title_short Deferiprone for transfusional iron overload and its roles in developing countries
title_full Deferiprone for transfusional iron overload and its roles in developing countries
title_fullStr Deferiprone for transfusional iron overload and its roles in developing countries
title_full_unstemmed Deferiprone for transfusional iron overload and its roles in developing countries
title_sort deferiprone for transfusional iron overload and its roles in developing countries
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84896702474&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/53835
_version_ 1681424208969596928